Ampaire Raises $19.0M Series B for Hybrid-Electric Aircraft

Pensata, Inc.

Pensata is a FinTech startup on a mission to eliminate preventable SME bankruptcies caused by the "optimism bias" of business owners. The ChallengeMany small and medium-sized enterprise (SME) bankruptcies stem from cash shortages driven by cognitive biases—like a founder's optimism that "it'll work out somehow." This human bias makes it incredibly difficult for CPAs to provide realistic cash flow advice. Furthermore, high-level advisory is time-consuming and relies heavily on an individual CPA's experience, creating a major bottleneck for accounting firms trying to scale their Client Advisory Services (CAS). Our SolutionWe built "Cashflowlens," an AI-powered CFO assistant designed to empower CPAs to transition into Fractional CFOs. Powered by our proprietary behavioral economics AI, the "Pensata Engine," our platform scientifically extracts a business owner's cognitive biases (such as risk tolerance and loss aversion) through interactive simulations. Based on this behavioral data and advanced mathematical models, Cashflowlens automatically adjusts business plans and cash flow forecasts from "optimistic" to highly accurate, "realistic" projections. Value for US CPAs & Accounting FirmsBy standardizing financial expertise, Pensata eliminates 80% of the time traditionally spent analyzing a client's cash flow. This empowers CPAs to focus on high-value, strategic decision-making and successfully scale their Fractional CFO services. Founded in 2026 and backed by a leadership team with deep expertise in global quantitative finance and law, Pensata is shifting the financial narrative from backward-looking reporting to predictive behavioral risk.

Craif Inc.

Craif is a molecular diagnostics company leveraging miRNA and machine learning for early cancer detection. Our proprietary platform, launched in Japan in 2022, powers the miSignal test, which screens for seven cancers (pancreatic, ovarian, esophageal, lung, breast, colorectal, and gastric) and has seen over 400% YoY revenue growth. In parallel with the commercialization of miSignal, we have started the clinical trial for the IVD test - pancreatic cancer diagnostic test for high risk population (e.g. diabetes, pancreatitis, etc.). This is a test seeking FDA/PMDA approval and planned to be reimbursed by insurance companies in the U.S. and reimbursed by the National Healthcare System in Japan. The clinical trial in Japan started in April 2024 and is planned to obtain approval in 2027H1. Craif USA was established in 2023 to bring this platform to the U.S. market, focusing on pancreatic cancer due to the high unmet need. We are currently enrolling cancers and high-risk controls to begin validation of the assay in a US population and are developing a US portfolio strategy that reflects the unmet clinical need and competitive landscape.